Ezetimibe Impurity 2 is a structurally related byproduct arising from the synthetic pathway of Ezetimibe, characterized by a substituted tetrahydrofuran ring fused to a phenyl ring, with a fluorinated ethyl side chain and a methoxy group at the 4-position of the aromatic moiety. The compound retains the core scaffold of Ezetimibe but exhibits a hydroxyl substitution at the terminal ethyl carbon, replacing the methylene group with a hydroxymethylene moiety. This modification introduces a polar hydroxyl functionality, altering its physicochemical properties compared to the parent drug. The impurity is formed via partial oxidation during esterification steps and serves as a critical HPLC reference standard for monitoring synthetic process fidelity.
On RequestC1[C@H](N(C(=O)O1)C(=O)CCC[C@@H](C2=CC=C(C=C2)F)O)C3=CC=CC=C3
InChI=1S/C20H20FNO4/c21-16-11-9-15(10-12-16)18(23)7-4-8-19(24)22-17(13-26-20(22)25)14-5-2-1-3-6-14/h1-3,5-6,9-12,17-18,23H,4,7-8,13H2/t17-,18-/m0/s1
AVAZNWOHQJYCEL-ROUUACIJSA-N